Engineered Anthrax PrAg Proteins for Tumor-Specific Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing protease-activated anthrax toxin systems for targeting tumors face limitations due to off-target effects caused by paracrine association of tumor-secreted proteases with non-tumor cells in the microenvironment, necessitating the development of more targeted approaches.
Innovation Solution
Engineered anthrax toxin protective antigen (PrAg) proteins with a membrane-anchored serine protease activation site instead of the furin activation site, allowing specific activation by overexpressed serine proteases on tumor cells, enabling targeted delivery of cytotoxic or therapeutic factors into tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If furin-activated PrAg is used to target tumors, then protease activation efficiency is improved, but off-target effects increase due to paracrine association with non-tumor cells
Solution Approach 1:
The patent applies local quality by replacing the universal furin activation site with tumor-specific protease activation sites (MMP-2, MMP-9, or uPA recognition sequences) at the specific location where proteolytic cleavage occurs in PrAg. This ensures that activation only occurs where these tumor-associated proteases are present, eliminating off-target effects in non-tumor cells while maintaining activation efficiency in tumor cells.
Solution Approach 2:
The patent changes the biochemical parameter of the activation site by substituting the furin recognition sequence (R-X-K-R) with alternative protease recognition sequences (e.g., MMP-2/9 or uPA sites). This parameter change redirects proteolytic activation from the ubiquitous furin pathway to tumor-specific protease pathways, thereby improving tumor targeting specificity while maintaining activation efficiency.
2Manufacturing precision
If uPA or MMP2/9-activated PrAg is used to target tumors, then tumor targeting specificity is improved, but off-target effects occur due to paracrine association in immune regulation and tissue remodeling
Solution Approach 1:
The patent applies local quality by engineering PrAg with activation sites specifically recognized by tumor-associated proteases (MMP-2, MMP-9, or uPA) rather than using furin sites. This localized modification ensures that proteolytic activation occurs only in the tumor microenvironment where these proteases are overexpressed, preventing off-target activation in normal tissues involved in immune regulation and physiological remodeling.
Solution Approach 2:
The patent changes the protease specificity parameter by replacing furin recognition sequences with MMP-2, MMP-9, or uPA recognition sequences in the PrAg molecule. This parameter change shifts the activation profile from broad (furin is ubiquitous) to targeted (MMP-2/9/uPA are tumor-associated), thereby improving tumor specificity while reducing harmful off-target effects in immune and remodeling processes.
3Manufacturing precision
If membrane-anchored serine protease activation sites are used in PrAg, then cell targeting specificity is improved, but device complexity increases
Solution Approach 1:
The patent applies local quality by making a focused modification at the protease activation site region of PrAg - replacing the furin recognition sequence with tumor-specific protease recognition sequences. This localized change achieves high tumor targeting specificity without requiring complex structural modifications elsewhere in the protein, thereby limiting the increase in engineering complexity to a manageable scope.
Solution Approach 2:
The patent changes a single critical parameter - the protease recognition sequence - while maintaining the overall PrAg structure and function. This targeted parameter change achieves improved cell targeting specificity with minimal complexity increase, as only the activation site sequence needs to be modified rather than the entire protein structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered PrAg proteins demonstrate enhanced specificity and efficacy in targeting tumor cells, reducing off-target effects and inducing cytotoxicity in various cancer types, including ovarian, cervical, pancreatic, and lung cancers, while being well-tolerated and effective in preclinical xenograft models.
Implementation Method 1
PrAg (83 kDa) bound to its cell-surface receptor(s) is proteolytically cleaved and activated by the protease furin (FURIN) or furin-like proprotein convertases in an exposed flexible loop to generate an active C-terminal 63-kDa PrAg fragment
Implementation Method 2
The newly-generated 63-kDa PrAg fragment remains receptor bound and catalyzes the formation of a PrAg/receptor oligomer that presents docking sites to enable up to four molecules of LF or EF to bind and translocate into the cytosol of a cell, through an endosomal PrAg-formed pore
Data Source
AI summary
Engineered anthrax protective antigen (PrAg) proteins are provided wherein the native furin activation site is replaced by the activation site of a membrane-anchored serine protease. These engineered PrAg proteins retain the ability to bind to cell surface PrAg receptors and be proteolytically activated. The proteins also retain the ability to form membrane pores. These engineered PrAg proteins can be used in methods of inducing pore formation in a cell, methods of inducing translocation of a selected compound or co-factor into a cell, and methods of treating disease, such as cancer, in a subject.